Exelixis (EXEL) Income from Continuing Operations (2010 - 2026)

Exelixis' (EXEL) quarterly Income from Continuing Operations came in at 210467000.0 in Q2 2026, up 31.86% year-on-year from 159616000.0 in Q2 2025, and down 13.93% quarter-over-quarter from 244528000.0 in Q1 2026.

Exelixis (EXEL) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Exelixis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 210467000.0 for Q2 2026.

  • On a quarterly basis, Income from Continuing Operations rose 31.86% year-over-year to 210467000.0 in Q2 2026; TTM through Apr 2026 was 833421000.0, a 29.5% increase from a year earlier, with the FY2026 full-year figure at 782570000.0, up 50.13% from the prior year.
  • Income from Continuing Operations slipped to 210467000.0 in Q2 2026 per EXEL's latest filing, from 244528000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 244528000.0 in Q1 2026 and bottomed at 30173000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 85518000.0 (2023), against an average of 112020647.06.
  • Across the five-year window, Income from Continuing Operations plunged 131.71% in 2022 and soared 11232.66% in 2024, its largest moves.
  • Year by year, Income from Continuing Operations stood at 30173000.0 in 2022, then surged by 383.43% to 85518000.0 in 2023, then jumped by 37.95% to 117973000.0 in 2024, then jumped by 64.09% to 193578000.0 in 2025, then increased by 8.72% to 210467000.0 in 2026.
  • Per Business Quant, the three latest EXEL Income from Continuing Operations figures stand at 210467000.0 (Q2 2026), 244528000.0 (Q1 2026), and 193578000.0 (Q4 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -37.09 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 227.36 Mn
4 NuCana 279.75 Bn 279.75 Bn - -3.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -26.94 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 362.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -453.82 Mn
10 Exelixis 14.38 Bn 13.60 Bn 590.86 Mn 210.47 Mn

Historic Data

Download Data
DateValue
Apr 3, 2026 210.47 Mn
Jan 2, 2026 244.53 Mn
Oct 3, 2025 193.58 Mn
Jul 4, 2025 184.85 Mn
Apr 4, 2025 159.62 Mn
Jan 3, 2025 139.86 Mn
Sep 27, 2024 117.97 Mn
Jun 28, 2024 226.12 Mn
Mar 29, 2024 37.32 Mn
Dec 29, 2023 85.52 Mn
Sep 29, 2023 1.04 Mn
Jun 30, 2023 81.18 Mn
Mar 31, 2023 40.03 Mn
Dec 30, 2022 -30.17 Mn
Sep 30, 2022 73.21 Mn
Jul 1, 2022 70.67 Mn
Apr 1, 2022 68.57 Mn
Dec 31, 2021 95.17 Mn
Oct 1, 2021 38.20 Mn
Jul 2, 2021 96.09 Mn